The recent approval of Blenrep (belantamab mafodotin) in the UK for the treatment of relapsed/refractory multiple myeloma marks a significant advance, supported by promising data from the DREAMM-7 and DREAMM-8 clinical trials. These trials demonstrated the efficacy of Blenrep combinations in extending progression-free survival, offering a new lifeline to patients battling this difficult-to-treat form of cancer. Key Opinion Leaders in Myeloma have been very vocal on X regarding their feelings about Blenrep.
Many experts in the field, such as Dr. Joseph Mikhael, the Chief Medical Officer of the International Myeloma Foundation, , have expressed optimism regarding Blenrep's regulatory approval in the UK, citing the drug's potential to notably improve patient outcomes. With its ability to prolong remission and possibly enhance overall survival, Blenrep is viewed as a therapeutic breakthrough. The inclusion of it in treatment plans signifies a leap forward in providing more robust options for myeloma patients.
While the efficacy of Blenrep is widely acknowledged, there remains a cautious conversation about its side effects, particularly ocular toxicity. Dr. Gareth Morgan highlighted the need to find an optimal dosing regimen that minimizes these side effects. This balanced approach could ensure patients benefit from Blenrep's therapeutic effects without compromising their quality of life. Dr. Rajkumar of the Mayo Clinic predicted at ASCO24 that Blenrep would make a comeback and stressed the ability to manage the ocular toxicities with appropriate dosing.
Dr. Rahul Banerjee of Fred Hutch Cancer Center expressed hopeful anticipation for a similar approval by the US FDA, noting the UK's proactive role in leading the way. Dr. Banerjee has also noted the unique nich Blenrep may fill in the multiple myeloma treatment arsenal, providing a helpful slide with treatment scenarios,
Some voices, like that of Dr. Mani Mohyuddin of Hunstman Cancer Institute, University of Utah.and Dr. Raj Chakraborty of Columbia University Irving Medical Center, have expressed some reservations of Blenrep in this setting. Dr. Mohyuddin has expressed concerns with regards to the patients' quality of life while on Blenrep. Dr. Charkraborty felt that despite the efficacy of the drug based on DREAMM-7, the ocular side effects, and access to other therapies potenitally outweigh the benefits.
Dr. Al-Ola A Abdallah of KU Medical Center has pointed out that Blenrep could significantly fill treatment gaps, especially in regions with limited access to the latest therapies. This highlights the drug's role not only as a treatment but as a beacon of hope for areas without extensive healthcare infrastructure.
Blenrep's approval in the UK, backed by the solid foundation of the DREAMM-7 and DREAMM-8 trials, marks a pivotal moment in the treatment landscape for relapsed/refractory multiple myeloma. As the myeloma community examines and reacts to these developments, the consensus is clear: although challenges remain, Blenrep offers a promising new chapter in the ongoing fight against this complex disease.